Geovax Labs Inc (OTCMKTS:GOVX)advertises itself as “a biotechnology company developing human immunotherapies and vaccines” that has historically been associated with the development of vaccines against infectious diseases. The stock is ripping right now, closing out the action last week with a jump of over 25% on Friday.

This action follows the company’s announcement the prior week that it “is now leveraging the knowledge and expertise it has validated in infectious diseases and expanding the applicability of MVA-VLP into immuno-oncology (IO) with highly promising results.” 

The big point here is: this is a stock to watch this week given the fresh momentum following a massive decline over recent months. It could be a mere on-off dead cat bounce. Or it could be more. 

Geovax Labs Inc (OTCMKTS:GOVX) promulgates itself as a clinical-stage biotechnology company that develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform in the United States and internationally.

It is developing various preventive vaccines against human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for chronic Hepatitis B infections and cancers.

The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; the HIV Vaccines Trial Network; Centers for Disease Control and Prevention; U.S. Army Research Institute of Infectious Disease; U.S. Naval Research Laboratory; Emory University; University of Pittsburgh; Georgia State University Research Foundation; University of Texas Medical Branch; the Institute of Human Virology at the University of Maryland; the Scripps Research Institute; the Burnet Institute; American Gene Technologies, Inc.; Viamune, Inc.; Vaxeal Holding SA; CaroGen Corporation; Virometix AG; U.S. Department of Defense; Geneva Foundation; Enesi Pharma; and Leidos, Inc. 

GeoVax Labs, Inc. was founded in 2001 and is based in Smyrna, Georgia.

While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn’t been the type of action GOVX shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -11% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities. Over the past month, shares of the stock have suffered from clear selling pressure, dropping by roughly -56%. 

Geovax Labs Inc (OTCMKTS:GOVX) pulled in sales of $210K in its last reported quarterly financials, representing top line growth of 125.1%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($216K against $1.6M, respectively).

Marimed Inc (OTCMKTS:MRMD)is another stock that has maybe – just maybe – started to spark some kind of rebound following precipitous declines. The stock has been getting clobbered despite posting some pretty strong face-value financial performance data given some of the intricacies of its relationship with GenCanna. 

That said, we have seen a possible line in the sand marked out by how it traded on Friday of last week. To provide some additional color, the company recently announced that it has received a special permit to allow its Panacea Wellness dispensary in Middleborough to merchandise cannabis products under the Massachusetts adult use program. 

According to the release, it will now proceed at the Cannabis Control Commission (CCC) for adult use final approval. The dispensary has already received town approval for medical use. The state’s Cannabis Control Commission is anticipated to give the go-ahead to open Panacea Wellness under the medical use program following the inspection of the dispensary earlier this week.

MRMD pulled in sales of $25.7M in its last reported quarterly financials, representing top line growth of 774%. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($3.5M against $31.1M, respectively).

Marimed Inc (OTCMKTS:MRMD) is an industry leader in the design, development, operation, funding, and optimization of medical cannabis cultivation, production, and dispensary facilities. MariMed’s team has developed state-of-the-art, regulatory-compliant legal cannabis facilities in multiple states.

These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. MariMed is on the forefront of precision dosed cannabis medicine for the treatment of specific medical conditions. MariMed branded products are being licensed and distributed in legal cannabis states across the country.

Moreover, MariMed Inc. provides consulting services for the design, development, operation, funding, and optimization of medical cannabis cultivation, production, and dispensary facilities. The company also develops and manages facilities for the cultivation, production, and dispensing of legal cannabis and cannabis-infused products under the Kalm Fusion brand name. In addition, it offers legal, accounting, human resources, and other corporate and administrative services.

Even in light of this news, MRMD has had a rough past week of trading action, with shares sinking something like -33% in that time. That said, chart support is nearby and we may be in the process of constructing a nice setup for some movement back the other way. What’s more, the listing has seen a growing influx of trading interest, with the stock’s recent average trading volume running nearly 140% above the average volume levels in play in this stock over the longer term. 

“This special permit brings Panacea Wellness another important step closer to participating in Massachusetts’s adult-use cannabis program,” said MariMed COO, Tim Shaw, “and keeps us on track to becoming the first company to provide top-quality cannabis medicines to the residents of Middleborough and the surrounding area.

CV Sciences Inc (OTCMKTS:CVSI)is in an interesting position for new money flow possibilities. Remember, this is one of the big pure-play growth opportunities in the CBD space. The stock launched thousands of percentage points of upside last year on that theme. 

Indeed, CVSI pulled in sales of $16.9M in its last reported quarterly financials, representing top line growth of 36.5%. In addition, the company has a strong balance sheet, with cash levels far exceeding current liabilities ($15.7M against $11.8M).

Yet now, we see it cracking under key support and finding a waterfall cascade of selling in response.

The catalyst should be understood. Obviously, some of this was technical. But the lion’s share of the blame goes to the company’s announcement that it intended to file for a Request of Continued Examination of its patent application No. 15/426,617 titled Pharmaceutical Formulations Containing Cannabidiol and Nicotine For Treating Smokeless Tobacco Addiction – an action that follows USPTO notifying the Company that the Patent Trial and Appeal Board had rejected the appeal to overturn the examiner’s decision to deny certain claims made within the patent application. “While the USPTO decision is disappointing, it’s important to recognize that this is not the end of the process and we plan to request continued examination.”

But there was also mitigating news: The company also just announced that it received the “NEXTY Consumer Choice Award” in the Supplement Category for the Company’s PlusCBD Oil Total Plant Complex Peppermint Spray.

According to the release, “Bestowed each year at Natural Products Expo East and West, the NEXTY Awards recognize natural products that eclipse others within their category in terms of innovation, inspiration, and integrity. All product candidates are evaluated via a rigorous submission and two-tiered judging process, and the winning products are selected based on targeted consumer feedback from 1,000 consumers who sample and score the products.”

CV Sciences Inc (OTCMKTS:CVSI) focuses on developing and commercializing novel therapeutics utilizing synthetic Cannabidiol (CBD). CVSI operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and, a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors, including nutraceutical, beauty care, specialty foods, and vape.

“Consumers choose and trust PlusCBD Oil because of our quality, purity and consistency. We offer the highest quality line of gluten-free, non-GMO full spectrum hemp CBD products in the industry and we’ve built our reputation on product purity and fundamentally sound research practices,” said Joseph Dowling, Chief Executive Officer of CV Sciences. “We are proud to be recognized by consumers as their favorite supplement, especially by those who are new to CBD.”